Multicenter Phase II study of TS-1 and gemcitabine combination therapy for elderly patients with unresectable pancreatic cancer.
Phase 2
Recruiting
- Conditions
- Elderly patients with unresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000003496
- Lead Sponsor
- Ochanomizu Gastrointestinal Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pulmonary fibrosis or interstitial pneumonia 2) Active double cancer, or history of cancer unless it was surgically removed intraepithrial cancer or is considered to be cured with no less that 10 years of recurrence-free 3) Severe complications, such as (1)poorly controlled diabetes melitus and hypertension (2)poorly controlled angina pectoris, heart failure, or myocardial infarction (3)active infection (4)other diseases with inadequate physical condition, such as ileus, bleeding tendency and diarrhea 4) Symptomatic metastasis in central nervous system 5) Severe mental disorders 6) History of drug hypersensitivity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Median survival time
- Secondary Outcome Measures
Name Time Method Safty, disease control rate, 1 year survival rate, progression-free survival